| Gene symbol | CLEC12A | Synonyms | CD371, CLL-1, CLL1, DCAL-2, MICL | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.31-p13.2 | dbXrefs | |
| Description | C-type lectin domain family 12 member A | ||||
| GTO ID | GTC3574 |
| Trial ID | NCT06017258 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | CD371 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD371-YSNVZ-IL18 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Trial of CLEc12a (CD371) Targeted ArmoRed Immune Effector Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia (CLEAR-AML) |
| Year | 2023 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 23-016 |
| Cohort 1 | |||||||
|
|||||||